Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jacob

Showing results (741-750 of 762) with videos related to

Pageof 77
Sort By:
JHLT Open|March 19, 2026
Association of community distress and risk of adverse events on the lung transplant waitlistAlan M Jacob, William Brandon, Colin Dunn, et al.
The Journal of Urology|October 7, 2018
Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic TherapyJoseph M Jacob, Elizabeth K Ferry, Laurie M Gay, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Circulation|October 2, 2013
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart AssociationSteven E Lipshultz, M Jacob Adams, Steven D Colan, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 25, 2010
Peri-operative outcomes for pancreatoduodenectomy in India: a multi-centric studyParul J Shukla, Savio G Barreto, Mms Bedi, et al.
Cardiovascular and Interventional Radiology|April 7, 2026
Optical See-Through and Video See-Through Head-Mounted Displays for Percutaneous Biopsies: A Comparative Phantom StudyAlice M Jacob, Alexander M C Böhner, Andreas Henkel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 StudySiamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology|July 30, 2023
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumorsJoseph M Jacob, Solomon L Woldu, Jennifer Linehan, et al.
Pageof 77

Showing results (741-750 of 762) with videos related to

Sort By:
Pageof 77
JHLT Open|March 19, 2026
Association of community distress and risk of adverse events on the lung transplant waitlistAlan M Jacob, William Brandon, Colin Dunn, et al.
The Journal of Urology|October 7, 2018
Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic TherapyJoseph M Jacob, Elizabeth K Ferry, Laurie M Gay, et al.
Nature Medicine|June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine|June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
Circulation|October 2, 2013
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart AssociationSteven E Lipshultz, M Jacob Adams, Steven D Colan, et al.
Nature Medicine|July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRoger Li, Paras H Shah, Tyler F Stewart, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 25, 2010
Peri-operative outcomes for pancreatoduodenectomy in India: a multi-centric studyParul J Shukla, Savio G Barreto, Mms Bedi, et al.
Cardiovascular and Interventional Radiology|April 7, 2026
Optical See-Through and Video See-Through Head-Mounted Displays for Percutaneous Biopsies: A Comparative Phantom StudyAlice M Jacob, Alexander M C Böhner, Andreas Henkel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 StudySiamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology|July 30, 2023
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumorsJoseph M Jacob, Solomon L Woldu, Jennifer Linehan, et al.
Pageof 77